

**Final Agenda**  
**60th meeting of the Committee for Risk Assessment**

**14-18 March 2022**

**Virtual meeting**

**14 March starts at 10.00**  
**18 March ends at 13.00**

***Times are Helsinki times***

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

***RAC/A/60/2022***  
***For adoption***

**Item 3 – Declarations of conflicts of interest to the Agenda**

**Item 4 – Appointment of (co-)rapporteurs**

4.1 Appointment of (co-)rapporteurs for CLH dossiers, restriction dossiers, authorisation applications, evaluation of occupational exposure limits

***For agreement***  
***Closed session***

**Item 5 – Report from other ECHA bodies and activities**

5.1 RAC Work Plan for all processes

***For information***

**Item 6 – Requests under Article 77(3)(c)**

n/a

## Item 7 – Health based exposure limits at the workplace

### 7.1 OEL dossiers

#### 1. Opinion development

1. 1,4-Dioxane
2. Isoprene

*For discussion and agreement*

## Item 8 – Harmonised classification and labelling (CLH)

### 8.1 General CHL issues

#### 1. Report from the January CLH WG

*RAC/60/2022/01  
For information*

#### 2. Renewal of Mandate of the CLH Working Group

*RAC/60/2022/02  
For agreement*

### 8.2 CLH dossiers

#### 1. Key issues discussion

1. Glyphosate (EC: 213-997-4, CAS: 1071-83-6)

*For information only*

#### 2. Hazard classes for agreement without plenary debate (A-list)

1. Reaction mass of: N,N'-Ethane-1,2 diylbis(decaneamide) 12-Hydroxy-N-[2-[1-oxydecyl]amino]ethyl]octadecanamide N,N'-Ethane-1,2-diylbis(12-hydroxyoctadecanamide)[Thixatrol plus]: *hazardous to the aquatic environment*
2.  $\alpha$ -methyl-1,3-benzodioxole-5-propionaldehyde: *skin sensitisation*
3. 2-[ethyl[3-methyl-4-[(5-nitrothiazol-2-yl)azo]phenyl]amino]ethanol [Disperse Blue 106]: *skin sensitisation*
4. 2,3-epoxypropyl neodecanoate: *skin sensitisation, mutagenicity*
5. Acetone oxime: *acute dermal toxicity, skin irritation, eye irritation, skin sensitisation, STOT SE, STOT RE, mutagenicity, carcinogenicity*
6. Propyl 3,4,5-trihydroxybenzoate: *acute toxicity, hazardous to the aquatic environment*
7. (3E)-dec-3-en-2-one: *physical hazards, acute toxicity, skin irritation, eye irritation, mutagenicity, carcinogenicity, reproductive toxicity, aspiration hazard, STOT SE, STOT RE, hazardous to the aquatic environment*
8. Benthiavalicarb-isopropyl (ISO): *acute toxicity, skin irritation, eye irritation, skin sensitisation, STOT SE, STOT RE, mutagenicity, hazardous to the aquatic environment*
9. Sulfur: *physical hazards, acute toxicity, skin irritation, skin sensitisation, STOT RE, carcinogenicity, mutagenicity, reproductive toxicity*

### 3. Hazard classes for agreement [with plenary debate]

1. (3E)-dec-3-en-2-one (EC: -; CAS: 18402-84-1): *skin sensitisation*
2. Benthialvalicarb-isopropyl (ISO); isopropyl [(S)-1-{{(R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl}carbamoyl}-2-methylpropyl]carbamate (EC: -; CAS: 177406-68-7): *physical hazards, carcinogenicity, reproductive toxicity*
3. Hexyl salicylate (EC: 228-408-6; CAS: 6259-76-3): *reproductive toxicity*
4. Multi-Walled Carbon Tubes (synthetic graphite in tubular shape) with a geometric tube diameter range  $\geq 30$  nm to  $< 3$   $\mu$ m and a length  $\geq 5$   $\mu$ m and aspect ratio  $> 3:1$ , including Multi-Walled Carbon Nanotubes, MWC(N)T (EC: -; CAS: -): *STOT RE, carcinogenicity*
5. Silver (EC: 231-131-3; CAS: 7440-22-4): *STOT RE, mutagenicity, carcinogenicity, hazardous to the aquatic environment*
6. Sulfur (EC: 231-722-6; CAS: 7704-34-9): *eye irritation, STOT SE*

***For discussion and adoption***

## Item 9 – Restrictions

### 9.1 General restriction issues

1. Report from the February Restriction WG

***RAC/60/2022/03  
For information***

2. Renewal of Mandate of the Restriction Working Group

***RAC/60/2022/04  
For agreement***

### 9.2 Restriction Annex XV dossiers

1. Conformity check and key issues discussion

1. PFAS in fire fighting foams

***For discussion and agreement***

2. Opinion development

1. Lead in outdoor shooting and fishing – fourth draft opinion

***For discussion***

2. 1,6,7,8,9,14,15,16,17,17,18,18-Dodecachloropentacyclo-[12.2.1.1<sup>6,9</sup>.0<sup>2,13</sup>.0<sup>5,10</sup>]octadeca-7,15-diene ("Dechlorane Plus"<sup>TM</sup>) – third draft opinion

***For discussion and adoption***

3. Substances containing polycyclic aromatic hydrocarbons (PAHs) in clay targets for shooting – first draft opinion

***For discussion***

4. 2,4-dinitrotoluene – **not** for discussion at RAC-60

## **Item 10 – Authorisation**

### **10.1 General authorisation issues**

1. Update on incoming/future applications
2. Update of technical guidance for rapporteurs ('Lines to take')

**RAC/60/2022/05**  
**Room document**  
**Confidential**  
**For information/discussion**

3. AfA Overview table
4. Report from the February AFA Working Group

**RAC/60/2022/06**  
**For information/discussion**

### **10.2 Authorisation applications**

#### **1. Discussion on key issues**

1. 13 applications for authorisation (chromium trioxide, 4-tert-OPnEO, 4-NPnEO) from November 2021 submission window

**For discussion**

### **10.3 Agreement on draft opinions**

#### **1. Draft opinions for agreement without plenary debate (A-list)**

1. 236\_SD\_Robur (1 use)
2. 239\_OPE\_NPE\_Prionics (1 use)
3. 240\_OPE\_Alexion (1 use)

**For agreement**

#### **2. Draft opinions for agreement with plenary debate**

1. 237\_CT\_Nobili (1 use)
2. 238\_CT\_Hueck (1 use)
3. 241\_CT\_Gessi (1 use)

**For discussion and agreement**

### **10.4 Adoption of opinions**

1. 224\_RR1\_EDC\_Eurenco (1 use)

**For discussion and adoption**

## **Item 11 – AOB**

## **Item 12 – Minutes of RAC-60**

1. Table with Summary Record of the Proceedings, and Conclusions and Action points from RAC-60

**For adoption**

## **PROVISIONAL TIMELINE FOR THE DISCUSSIONS AT RAC-60**

Please note that this timeline is provisional. Changes can be made before and during the meeting in order to accommodate the discussions.

### **Monday 14 March 2022: Morning session**

- Item 1 – Welcome and Apologies
- Item 2 – Adoption of the Agenda
- Item 3 – Declarations of conflicts of interest to the Agenda
- Item 5 – RAC Work Plan for Restriction, Authorisation and C&L processes
- Item 1 – ECHA Executive Director’s address to RAC-60
- Item 7 – OEL

### **Monday 14 March 2022: Afternoon session**

- Item 7 – OEL
- Item 9 – Restrictions
- Item 8 – CLH dossiers
- Item 9 – Restrictions

### **Tuesday 15 March 2022: Morning session**

- Item 9 – Restrictions

### **Tuesday 15 March 2022: Afternoon session**

- Item 10 – Authorisation applications

### **Wednesday 16 March 2022: Morning session**

- Item 8 – CLH dossiers

### **Wednesday 16 March 2022: Afternoon session**

- Item 8 – CLH dossiers

### **Thursday 17 March 2022: Morning session**

- Item 8 – CLH dossiers

### **Thursday 17 March 2022: Afternoon session**

- Item 8 – CLH dossiers

### **Friday 18 March 2022: Morning session**

- Item 8 – CLH dossiers
- Item 5 – Appointment of (co-)rapporteurs for CLH dossiers, restriction dossiers, authorisation applications, evaluation of occupational exposure limits
- Item 11 – AOB
- Item 12 – Summary records

\*\*\*